Sucampos Lubiprostone safe and effective in Chronic Idiopathic Constipation

Sucampo have announced results from 3 open-labeled, long-term clinical trials of lubiprostone (AMITIZA) in patients with Chronic Idiopathic Constipation (CIC).

Vertexs VX-770 improves lung function in cystic fibrosis

Data presentes at the 31st European Cystic Fibrosis Society Meeting shows Vertex’s VX-770 to improve lung function in cystic fibrosis patients.

Amitiza (lubiprostone) relieves IBS in Phase III

Chloride channel agonist Amitiza (lubiprostone) had been shown to significantly relieve symptoms of Irritable Bowel Syndrome with Constipation (IBS-C).

Sucampo’s Amitiza approved for Constipation predominant IBS

The FDA has approved Amitiza for the addtitional indication of irritable bowel syndrome with constipation (IBS-C) in women 18 years of age or older. It was previously launched in the US forchronic idiopathic constipation in 2006